Angiodynamics, Inc. (ANGO) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AngioDynamics Advances Pulmonary Embolism Study With New Clot Removal System
The APEX-Return study, officially titled “Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness,” aims to test a new way to treat serious lung blood clots. It focuses on safety and basic effectiveness, and it matters because better, faster clot treatment can lower deaths and hospital costs.
The study tests AngioDynamics’ AlphaVac MMA F1885 System together with the AlphaReturn Blood Management System, both device-based treatments. The goal is to remove clots while filtering and returning the patient’s own blood, which may cut blood loss and reduce the need for transfusions.
This is an interventional study with a single treatment group, so every patient gets the same device procedure instead of being randomized. There is no blinding, meaning doctors and patients know the treatment used, and the main goal is direct treatment rather than diagnosis or prevention.
The trial was first submitted on November 25, 2025, marking the start of regulatory and set-up work before patient enrollment. It is currently listed as “Not yet recruiting,” and the latest update on February 16, 2026 signals fresh progress on protocol or site preparation even though results are not yet posted.
For investors, this update shows AngioDynamics pushing deeper into mechanical clot removal, a growing space that also includes players like Inari Medical and Penumbra. If the study confirms good safety and solid outcomes, it could support higher adoption of the AlphaVac and AlphaReturn systems, which in turn can lift revenue expectations, improve sentiment around ANGO, and raise questions about market share shifts across the pulmonary embolism device segment.
The APEX-Return study remains active in its set-up phase and has been recently updated, with detailed information and ongoing changes available through the ClinicalTrials.gov portal.
To learn more about ANGO’s potential, visit the Angiodynamics, Inc. drug pipeline page.